Abstract
10 patients suffering from Parkinson's disease were selected for this study because of their predictable fluctuations in motor performances and nocturnal akinesia. 7 patients out of these 10, were treated with a sustained release formulation of L-Dopa plus PDDI (Madopar HBS) for six months. The remaining 3 patients dropped out of the study within the initial 30 days of treatment. The clinical evaluation and the diary of the patients showed an improvement of the fluctuations, nocturnal akinesia and 'Off period dystonia'. The dosage was 60% greater on average than the corresponding dose of the standard drug. The improvement remained constant during the trial period and no side effects or complications were reported.
| Original language | English |
|---|---|
| Pages (from-to) | 29-38 |
| Number of pages | 10 |
| Journal | New Trends in Clinical Neuropharmacology |
| Volume | 3 |
| Issue number | 1 |
| Publication status | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
- Pharmacology
Cite this
Oral sustained-release preparation of L-Dopa in the management of fluctuations in Parkinson's disease : 6 months follow-up. / Stocchi, F.; Bragoni, M.; Monge, A.; Bravi, D.; Giorgi, L.; Viselli, F.; Ruggieri, S.
In: New Trends in Clinical Neuropharmacology, Vol. 3, No. 1, 1989, p. 29-38.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oral sustained-release preparation of L-Dopa in the management of fluctuations in Parkinson's disease
T2 - 6 months follow-up
AU - Stocchi, F.
AU - Bragoni, M.
AU - Monge, A.
AU - Bravi, D.
AU - Giorgi, L.
AU - Viselli, F.
AU - Ruggieri, S.
PY - 1989
Y1 - 1989
N2 - 10 patients suffering from Parkinson's disease were selected for this study because of their predictable fluctuations in motor performances and nocturnal akinesia. 7 patients out of these 10, were treated with a sustained release formulation of L-Dopa plus PDDI (Madopar HBS) for six months. The remaining 3 patients dropped out of the study within the initial 30 days of treatment. The clinical evaluation and the diary of the patients showed an improvement of the fluctuations, nocturnal akinesia and 'Off period dystonia'. The dosage was 60% greater on average than the corresponding dose of the standard drug. The improvement remained constant during the trial period and no side effects or complications were reported.
AB - 10 patients suffering from Parkinson's disease were selected for this study because of their predictable fluctuations in motor performances and nocturnal akinesia. 7 patients out of these 10, were treated with a sustained release formulation of L-Dopa plus PDDI (Madopar HBS) for six months. The remaining 3 patients dropped out of the study within the initial 30 days of treatment. The clinical evaluation and the diary of the patients showed an improvement of the fluctuations, nocturnal akinesia and 'Off period dystonia'. The dosage was 60% greater on average than the corresponding dose of the standard drug. The improvement remained constant during the trial period and no side effects or complications were reported.
UR - http://www.scopus.com/inward/record.url?scp=0024435179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024435179&partnerID=8YFLogxK
M3 - Article
VL - 3
SP - 29
EP - 38
JO - New Trends in Clinical Neuropharmacology
JF - New Trends in Clinical Neuropharmacology
SN - 0393-5345
IS - 1
ER -